NxThera spinout NxPhase lands $10m for vapor ablation tech

NxPhase Medical – spun out of NxThera when Boston Scientific bought it this year– has raised more than $10 million, according to a recent U.S. Securities and Exchange Commission filing.

Maple Grove, Minn.–based NxPhase is focused on using convective thermal water vapor to treat prostate, kidney, and bladder cancer, according to its LinkedIn page. And SEC Form D dated Nov. 29 says it is seeking to raise more than $18 million in its present money-raise.

NxThera’s Rezūm benign prostatic hyperplasia device uses steam to ablate excess prostate tissue. Boston Scientific closed on its $406 million acquisition of NxThera in April. The deal included the spin out of NxPhase, a new company to commercialize technology for treating cancer.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW